T K Jeffery
Overview
Explore the profile of T K Jeffery including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
262
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Southwood M, Jeffery T, Yang X, Upton P, Hall S, Atkinson C, et al.
J Pathol
. 2007 Nov;
214(1):85-95.
PMID: 17992660
The bone morphogenetic protein (BMP) type II receptor (BMPR-II) is predominantly expressed on the vascular endothelium in the adult lung. Although mutations in BMPR-II are known to underlie many cases...
2.
Jeffery T, Morrell N
Prog Cardiovasc Dis
. 2003 Jan;
45(3):173-202.
PMID: 12525995
Clinical pulmonary hypertension is characterized by a sustained elevation in pulmonary arterial pressure. Pulmonary vascular remodeling involves structural changes in the normal architecture of the walls of pulmonary arteries. The...
3.
Jeffery T, Wanstall J
Pharmacol Ther
. 2001 Dec;
92(1):1-20.
PMID: 11750034
Pulmonary vascular remodelling is an important pathological feature of pulmonary hypertension, leading to increased pulmonary vascular resistance and reduced compliance. It involves thickening of all three layers of the blood...
4.
Wanstall J, Jeffery T, Gambino A, Lovren F, Triggle C
Br J Pharmacol
. 2001 Oct;
134(3):463-72.
PMID: 11588100
1. Vasorelaxant properties of three nitric oxide (NO) donor drugs (glyceryl trinitrate, sodium nitroprusside and spermine NONOate) in mouse aorta (phenylephrine pre-contracted) were compared with those of endothelium-derived NO (generated...
5.
Jeffery T, Wanstall J
Can J Physiol Pharmacol
. 2001 Apr;
79(3):227-37.
PMID: 11294599
In pulmonary hypertension, changes in pulmonary vascular structure and function contribute to the elevation in pulmonary artery pressure. The time-courses for changes in function, unlike structure, are not well characterised....
6.
Jeffery T, Wanstall J
Eur J Pharmacol
. 2001 Apr;
416(1-2):123-31.
PMID: 11282121
This study investigated whether pulmonary vascular remodelling in hypoxic pulmonary hypertensive rats (10% oxygen; 4 weeks) could be prevented by treatment, during hypoxia, with amlodipine (10 mg/kg/day, p.o.), either alone...
7.
Jeffery T, Bryan-Lluka L, Wanstall J
Eur J Pharmacol
. 2000 May;
396(2-3):137-40.
PMID: 10822067
In this study, the aim was to determine whether 5-hydroxytryptamine (5-HT) removal by the pulmonary endothelium is reduced in 1-week hypoxic, pulmonary hypertensive rats by directly measuring [3H]5-HT uptake in...
8.
Jeffery T, Wanstall J
Br J Pharmacol
. 1999 Dec;
128(7):1407-18.
PMID: 10602319
1. Hypoxic pulmonary hypertension in rats (10% O2, 4 weeks) is characterized by changes in pulmonary vascular structure and function. The effects of the angiotensin converting enzyme inhibitor perindopril (oral...
9.
Wanstall J, Jeffery T
Drugs
. 1999 Jan;
56(6):989-1007.
PMID: 9878988
Pulmonary hypertension (mean pulmonary arterial pressure > 20mm Hg at rest or > 30mm Hg during exercise) occurs (i) as primary pulmonary hypertension (no known underlying cause), (ii) as persistent...
10.
Jeffery T, Wanstall J
J Cardiovasc Pharmacol
. 1998 Aug;
32(2):213-9.
PMID: 9700982
Milrinone and 6-bromo-8(methylamino)imidazo[1,2a]pyrazine-2-carbonitrile [SCA40; phosphodiesterase (PDE) III inhibitors], zaprinast (PDE V inhibitor), and 3-isobutyl-1-methyl xanthine (IBMX; nonselective PDE inhibitor) were examined on main pulmonary arteries from control rats and rats...